美股异动丨礼来涨超3%，新减肥药试验结果超市场预期

Core Viewpoint - Eli Lilly (LLY.US) shares rose over 3%, reaching $1024.5, following the announcement of positive results from a clinical trial of retatrutide, which showed significant weight loss and pain relief in participants [1] Group 1: Clinical Trial Results - Patients receiving the highest dose of retatrutide experienced a weight loss exceeding 23% over 68 weeks [1] - The self-reported results indicated that participants experienced over a 62% reduction in knee pain [1] - The trial results surpassed Wall Street's expectations, which had predicted weight loss in the range of 20% to 23% and at least a 50% reduction in knee pain [1] Group 2: Market Reaction - Following the announcement, Eli Lilly's stock price increased by more than 3% [1] - Some participants opted to withdraw from the clinical trial due to the significant weight loss effects [1]